• Novavax’s new Ebola vaccine candidate has proved to assist healthy people develop an immune response in an early trial against the almost lethal virus. The vaccine is a Ebola virus glycoprotein (GP) recombinant nanoparticle. It targets a particular Ebola strain which is responsible for most of the Ebola cases in West Africa.
  • According to the company’s presentation on its website, the trial of the vaccine was started in started in early February in Australia. The dose-escalation trial of the vaccine was tried on 230 healthy adults, ranging from 18 to 49 years, with and without the adjuvant.
  • “These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans,” said Dr. Greg Glenn, Novavax’s research chief, in a statement.

Share This Article